Gil Rabinovici, MD
Neurology · San Francisco, CANPI 1871644468
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $118,070 of the $126,188 with a category attached, or 93.6%. 12 manufacturers reported payments, led by Janssen Research & Development, LLC at 28.3% of the total. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $1433.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$36K
- Eli Lilly$24K
- Merck$22K
- F. Hoffmann-la Roche AG$19K
- Eisai Inc.$12K
- Novo Nordisk AS$4K
- plus $10K from 6 others
Across 13 payments — averaging $133,919 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.6M
- GE HealthCare$142K
- F. Hoffmann-la Roche AG$750
What the payments were for
- Consulting fees$118,07094%
- Travel & lodging$6,2285%
- Food & beverage$1,8901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 7 | $35,700 |
| Eli Lilly | 19 | $23,524 |
| Merck | 26 | $21,521 |
| F. Hoffmann-la Roche AG | 12 | $18,900 |
| Eisai Inc. | 14 | $12,171 |
| Novo Nordisk AS | 4 | $4,223 |
| C2n Diagnostics, LLC | 1 | $2,995 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,419 |
| GE HealthCare | 1 | $2,400 |
| Genentech USA, Inc. | 1 | $2,295 |
| Biogen | 1 | $24 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$10,931
- PRECIVITYAD2$2,995
How this compares
$126,188 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 12 | $4,340 |
| Memantine Hcl | 16 | $1,761 |
| Memantine Hcl ErMemantine Hcl | 11 | $1,736 |
| Donepezil Hcl | 48 | $576 |
| Escitalopram Oxalate | 17 | $345 |
| Citalopram HbrCitalopram Hydrobromide | 27 | $224 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.